Logistics, Regulation, and Security: The Impasse on Storing Cannabis in Brazil

The possibility of storing cannabis-based products in Brazil was back on the agenda at Deusa Cast, where experts discussed regulatory advances, legal challenges, and logistical impacts. 

Lawyer Larissa Meneghel, former Anvisa civil servant and specialist in health law, Paula Scanapieco, commercial manager at Mile Express, and Juliana Sousa, lawyer specializing in customs and criminal law, brought different perspectives on the topic, which still raises questions in the sector.

International Logistics vs. Brazilian Reality

According to Paula Scanapieco, from a logistical standpoint, the current model - without storage in Brazil, already works well. She highlighted that the operation is structured to serve patients directly from the stock held in the United States. “As long as there is no stock in Brazil, we continue with a logistics system that has been refined over the years, ensuring agility and safety for the patient,” she emphasized.
Legal and Inspection Hurdles

On the other hand, lawyer Juliana Sousa pointed out that stock within Brazil faces a series of legal complications, especially due to the lack of effective inspection. “When it comes to products subject to special control, thinking about storage is complex. A stricter control is needed to ensure that the medication is delivered to the authorized patient,” she explained.

Difference between RDCs 660 and 327

In Larissa Meneghel's assessment, the issue of stock is not legally sustainable because RDC 660 was not created for this purpose, but to allow individual patient access to unregulated products in Brazil. RDC 327, on the other hand, establishes rules for sales and storage in national territory. “There is no justification for having stock via 660. If there is, it is because there is an attempt to circumvent the regulations. Each RDC was created with its purpose and should coexist clearly,” she stated.

Read Also

How RDC 660 ensures diversified products and support for doctors in different diseases

RDC 327 Review: impact on the Brazilian medicinal cannabis market in 2025

Despite recognizing the importance of the discussion, the experts emphasized that, so far, Brazilian legislation does not authorize the formation of stocks of cannabis-based products in the country, maintaining restricted access to the individual importation model.

Follow the viewpoints of the interviewees in the video below: